5-(2-呋喃基)-5-甲基咪唑烷-2,4-二酮 | 4615-71-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 中文名称: 5-(2-呋喃基)-5-甲基咪唑烷-2,4-二酮
• 英文名称: 5-furan-2-yl-5-methylimidazolidine-2,4-dione
• 英文别名: 5-furan-2-yl-5-methyl-imidazolidine-2,4-dione；5-(furan-2-yl)-5-methylimidazolidine-2,4-dione；5--5-methyl-hydantoin；5-(2-Furyl)-5-methylimidazolidine-2,4-dione
• CAS: 4615-71-8
• 化学式: C₈H₈N₂O₃
• mdl: MFCD00461529
• 分子量: 180.163
• InChiKey: CLYDEKUAEQOFIL-UHFFFAOYSA-N

物化性质

• 熔点：
  176-178 °C
• 密度：
  1.294±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  71.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  5-(2-呋喃基)-5-甲基咪唑烷-2,4-二酮 在 sodium hydroxide 、 氯 作用下， 生成 3-氯-5-(呋喃-2-基)-5-甲基咪唑烷-2,4-二酮
  参考文献：
  名称：

  Hydantoins as antitumor agents

  摘要：

  A series of 27 hydantoins was prepared and tested as antitumor agents. These were variously substituted in the 5 position but with special emphasis on the substituents (chloro, acetyl, chloroacetyl, and methyl) in the 1 and/or 3 positions. The most active compound was 5,5-bis(4-chlorophenyl)-1,3-dichlorohydantoin with a T/C value of 190% against P-388 lymphocytic leukemia in mice.

  DOI：

  10.1021/jm00214a031
• 作为产物：
  描述：

  2-乙酰基呋喃 、 氰化钾 生成 5-(2-呋喃基)-5-甲基咪唑烷-2,4-二酮
  参考文献：
  名称：

  SYNTHESIS OF α-ALKYL-SUBSTITUTED AMINO ACIDS AND DERIVATIVES

  摘要：

  不可用。

  DOI：

  10.1139/v65-163

文献信息

• [EN] AMIDOALKYLPIPERAZINYL DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES<br/>[FR] DÉRIVÉS D'AMIDOALKYLPIPÉRAZINYLE POUR LE TRAITEMENT DE MALADIES DU SYSTÈME NERVEUX CENTRAL
  申请人：ADAMED SP ZOO

  公开号：WO2013001498A1

  公开（公告）日：2013-01-03

  The invention relates to novel amidoalkylpiperazinyl derivatives of tricyclic heterocyclic systems of general formula (I), wherein Z represents -NH- and X represents -S-, or Z represents -S- and X represents >C=C<; R1 represents H or -CH3, R6 and R7 both represent H, n is an integer from 0 to 4 inclusive, G represents a cyclic amide or imide moiety, and optical isomers, geometric isomers, and pharmaceutically acceptable salts thereof. The compounds may be useful for the treatment and/or prevention of the central nervous system disorders.

  该发明涉及一种新型三环杂环系统的酰胺基烷基哌嗪衍生物，其一般式为（I），其中Z代表-NH-，X代表-S-，或Z代表-S-，X代表>C=C<；R1代表H或-CH3，R6和R7均代表H，n为0至4的整数，G代表环酰胺或亚酰胺基团，以及其光学异构体、几何异构体和药学上可接受的盐。这些化合物可能对中枢神经系统疾病的治疗和/或预防有用。
• CARBINOL DERIVATIVES HAVING CYCLIC LINKER
  申请人：Yamaguchi Yuki

  公开号：US20100048610A1

  公开（公告）日：2010-02-25

  [Object] To provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate.

  提供一种新型的LXRβ激动剂，可用作预防和/或治疗动脉粥样硬化；动脉硬化，如糖尿病引起的动脉硬化；血脂异常；高胆固醇血症；与脂质相关的疾病；由炎性细胞因子引起的炎症性疾病；过敏性皮肤病；糖尿病；或阿尔茨海默病的治疗剂。【解决手段】以下一般式（I）所表示的羟甲基化合物或其盐，或其溶剂化合物。
• SUBSTITUTED CARBINOL COMPOUND HAVING CYCLIC LINKER
  申请人：Kowa Company, Ltd.

  公开号：EP2281817A1

  公开（公告）日：2011-02-09

  It is to provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. It is a carbinol compound represented by the following general formula (I) or salt thereof, or their solvate.

  本发明旨在提供一种新型 LXRβ 激动剂，可作为动脉粥样硬化、动脉硬化（如糖尿病引起的动脉硬化）、血脂异常、高胆固醇血症、血脂相关疾病、由炎性细胞因子引起的炎症性疾病、皮肤病（如过敏性皮肤病）、糖尿病或阿尔茨海默病的预防和/或治疗药物。 它是由以下通式(I)或其盐或它们的溶解物所代表的醇化合物。
• SUBSTITUTED CARBINOL COMPOUND
  申请人：Kowa Company, Ltd.

  公开号：EP2098515B1

  公开（公告）日：2012-02-08
• US8168666B2
  申请人：——

  公开号：US8168666B2

  公开（公告）日：2012-05-01